undefined

GE Yang

Associate Professor/ Graduate student’ Supervisor

Email: geyang19861026@icloud.com

Bio

  • Dr. Yang Ge, graduated from Second Military Medical University, and joined as associated Professor in the School of Public Health, Shanghai Jiao Tong University School of Medicine. Dr. Yang Ge has supported by various research grants including the National Natural Science Foundation of China (NSFC), the Project of Shanghai Science and Technology Commission, and the New Teacher Project of Shanghai Jiao Tong University.

Research interests:

  • Pathogenesis of chronic diseases including diabetes and digestive system cancer in special population regulated by bad lifestyle habits. Focus on the correlation between pollutant induction and precise prevention in preventive medicine, combine the interdisciplinary research of molecular toxicology, immunology, epidemiology and statistics, and combine the cohort, clinical data with physiology and pathology. From the perspective of molecular markers and protein network mechanism, the effects of environmental and food contaminants and poor diet habits on the occurrence and development of diseases were expounded.

  • 1. Mechanisms of foodborne pollutants regulating metabolic disorders and inflammatory responses

    To explore the correlation between food safety and chronic injury of human body, and study the toxic effects of the most widely polluted polycyclic aromatic hydrocarbons (benzopyrene) pollutants in the world, such as liver lipid metabolism disorder, inflammation and diabetes induced by poor diet habits such as cigarette and barbecue tar. To provide a theoretical basis for precise prevention

    2. Molecular markers of malignant metastasis of digestive system tumors

    The relationship between liver microenvironment and malignant metastasis of tumor was studied, and the target molecule-downstream signaling pathway network regulation model was established by integrating functional tests with downstream signaling pathways. The clinical cohort information base of postoperative administration of sorafenib for hepatocellular carcinoma was established. It was found that miR-200a/-183 was a potential regulator of the UGT1A gene family in patients with high expression of the sorafenib metabolic enzyme UGT1A9 in the liver. It provides a potential target for multifactorial tumor therapy

    3. Correlation between clinical data analysis and disease prognosis

    Based on clinical data, the prognosis of liver cancer was predicted to be related to tumor size, poor differentiation, hepatitis B virus infection, gallstones and lymph node metastasis. Combined with prospective validation studies, it can support the selection of treatment mode and provide theoretical support for clinical medicine.

Publications in recent 3 years (First or Corresponding author):

  • 1. Benzo[a]pyrene stimulates miR-650 to promote hepatocellular carcinomas metastasis via target SOCS3/JAK/STAT3 cascades J Mol Cell Biol ,2021 First author.

  • 2. Exosomal CD44 cooperates with integrin α6β4 to support tumor metastasis via regulating tumor cell motility and target host cell activation. Engineering, 2020 Corresponding author

  • 3. Hepatocellular Carcinoma-derived Exosomes in Organotropic Metastasis, Recurrence and Early Diagnosis Application. Cancer Lett 2019 First author

  • 4. Transarterial chemoembolization versus percutaneous microwave coagulation therapy for recurrent unresectable intrahepatic cholangiocarcinoma: Development of a prognostic nomogram. Hepatobiliary & Pancreatic Diseases International.2020 First author

  • 5. A single-center retrospective analysis of childhood hepatoblastoma in China. Gland Surgery 2020 Corresponding author

  • 6. Cholangiocarcinoma Susceptible to Adjuvant Treatment After Resection: A Clinical Deep Learning Approach Frontiers in Oncology 2020 co-First author

  • 7. Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma. Cancer Letters 454 (2019) 14-25 First author